Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.
about
Modelling hepatitis C therapy--predicting effects of treatmentClinical Laboratory Testing in the Era of Directly Acting Antiviral Therapies for Hepatitis CReal-Time PCR Assays for the Quantification of HCV RNA: Concordance, Discrepancies and Implications for Response Guided Therapy.Reply to Harrington et al.Performance of the New Aptima HCV Quant Dx Assay in Comparison to the Cobas TaqMan HCV2 Test for Use with the High Pure System in Detection and Quantification of Hepatitis C Virus RNA in Plasma or SerumSASLT guidelines: Update in treatment of Hepatitis C virus infection.HCV kinetic and modeling analyses indicate similar time to cure among sofosbuvir combination regimens with daclatasvir, simeprevir or ledipasvir.Prevalence of end of treatment RNA-positive/sustained viral response in HCV patients treated with sofosbuvir combination therapiesHepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection: A Systematic Review and Meta-analysis.Differences between quantification of genotype 3 hepatitis C virus RNA by Versions 1.0 and 2.0 of the COBAS AmpliPrep/COBAS TaqMan HCV Test.Shortening the duration of therapy for chronic hepatitis C infection.Significance of HCV RNA monitoring in the era of new potent therapies.Is response guided therapy dead? Low cure rates in patients with detectable hepatitis C virus at week 4 of treatment.Implications of HCV RNA level at week 4 of direct antiviral treatments for hepatitis C.European Multicenter Study on Analytical Performance of DxN Veris System HCV AssayHepatitis C RNA assay differences in results: Potential implications for shortened therapy and determination of Sustained Virologic ResponseResurrection of response-guided therapy for sofosbuvir combination therapies.On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvir.Breaking Down Barriers to Care in Hepatitis C Virus Infection.Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials.Optimising diagnosis of viraemic hepatitis C infection: the development of a target product profile.Values, preferences and current hepatitis B and C testing practices in low- and middle-income countries: results of a survey of end users and implementers.Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.Short-term histological evaluations after achieving a sustained virologic response to direct-acting antiviral treatment for chronic hepatitis C
P2860
Q26864673-F7413E59-176D-4745-AC45-5FCD0DA734EAQ28080225-7A78C531-FC45-420A-8C16-71A5585C8C44Q35746376-E99161BB-3011-4E93-8C81-E040E0770986Q35974458-4EC229B8-0063-4EE6-8FE5-0EE8B9714B94Q36734896-F93C3E32-27FC-470F-8CC9-7FEAF93808BCQ37216507-C87C5C8B-5B0C-4B78-BAAD-33D02B3C008FQ37368417-0914A0F7-81B1-4A6E-874A-C24419247035Q37671974-4EB0D29A-0D8F-4880-ABF1-47BB086F512BQ37692611-A928B363-9851-4131-821C-2A553A2539FEQ38376757-BE6B9C10-AF9D-41DC-8D90-02C55CB9A220Q38627508-A08819F0-28B5-42F6-87BE-D71E30A5484BQ38899447-420E52E9-F640-4DBC-9B19-3731976ABA88Q39194161-E8184415-91DB-4942-ADDD-9716FCB90EBEQ40171277-8B69EE3A-C064-4F0B-88C4-C7931EB11B64Q40348977-A3AF1244-17EF-47E1-AD2B-D17977A02DA0Q40529775-0202776C-7B6F-44C0-A1D4-EF2C8468E6A9Q40652760-D6E23C0B-C02B-488A-9BC2-AEB1D56217C1Q40671013-117E92D0-188B-4240-8FCB-5C6B4091FD39Q42645615-71EFC453-F208-493E-9455-96FFBB79C7BEQ42979154-12C700E5-6090-46EC-AAFB-432116791D90Q46388033-88447E6F-D40E-482A-90CE-0EBF1806784DQ46707427-40827675-4588-44C9-86A9-25F983A7AF16Q47561388-57C2FCB0-61A6-465F-8AFD-7EEAA1C67A4AQ52326653-75192310-2EC2-4C16-8D3D-F02D1FCDCA6AQ58579652-5EE35C7E-9BF8-4AB9-8B50-38D3BA4800E3
P2860
Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.
@ast
Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.
@en
type
label
Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.
@ast
Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.
@en
prefLabel
Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.
@ast
Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.
@en
P2093
P2860
P356
P1476
Utility of hepatitis C viral load monitoring on direct-acting antiviral therapy.
@en
P2093
Amy Nelson
Anita Kohli
Anu Osinusi
Henry Masur
Sreetha Sidharthan
Zayani Sims
P2860
P304
P356
10.1093/CID/CIV170
P407
P577
2015-03-02T00:00:00Z